Last $1.09 USD
Change Today +0.05 / 4.81%
Volume 176.0K
CDXC On Other Exchanges
Symbol
Exchange
Berlin
As of 5:20 PM 08/28/14 All times are local (Market data is delayed by at least 15 minutes).

chromadex corp (CDXC) Snapshot

Open
$1.05
Previous Close
$1.04
Day High
$1.09
Day Low
$1.02
52 Week High
03/21/14 - $2.15
52 Week Low
09/20/13 - $0.71
Market Cap
116.1M
Average Volume 10 Days
141.8K
EPS TTM
$-0.09
Shares Outstanding
106.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHROMADEX CORP (CDXC)

Related News

No related news articles were found.

chromadex corp (CDXC) Related Businessweek News

No Related Businessweek News Found

chromadex corp (CDXC) Details

ChromaDex Corporation, a natural products company, through its subsidiaries, discovers, acquires, develops, and commercializes proprietary-based ingredient technologies. The company utilizes its wholly owned business units, including ingredient technologies, catalog of natural product fine chemicals, chemistry and analytical testing services, and product regulatory and safety consulting services. It provides science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic, and pharmaceutical industries. The company’s products and services in development include Nicotinamide riboside, a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, and cognitive function, as well as anti-aging effects; Pterostilbene and caffeine co-crystal that are ingredients for the formulation of energy products; and Anthocyanins, which are secondary plant metabolites for use as candidates in the pharmaceutical, dietary supplement, and food colorants industries. It also provides a range of contract services ranging from routine contract analysis for the production of dietary supplements, cosmetics, foods, and other natural products to elaborate contract research for clients in these industries; and consulting services in the areas of regulatory support, new ingredient or product development, risk management, and litigation support, as well as product regulatory approval and scientific advisory services. The company markets and sells its products directly in the United States and Canada; and through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. ChromaDex Corporation is headquartered in Irvine, California.

chromadex corp (CDXC) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $276.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $204.9K
Compensation as of Fiscal Year 2013.

chromadex corp (CDXC) Key Developments

ChromaDex Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter Ended June 28, 2014

ChromaDex Corporation reported unaudited consolidated earnings results for the second quarter ended June 28, 2014. For the three months ended June 28, 2014, the company reported net sales of $3,856,154, an increase of approximately 42% as compared to $2,706,896 for the three months ended June 29, 2013. This increase was largely due to increased sales in the proprietary ingredient segment which grew to $1,721,872, an increase of 155% as compared to the sales of $674,175 in second quarter of 2013 and a sequential increase of 52% as compared to ingredient sales of $1,136,309 in first quarter of 2014. The net loss attributable to common stock holders was $1,653,142 or $0.02 per basic and diluted share as compared to a net loss of $1,020,866 or $0.01 per basic and diluted share for second quarter of 2013. Operating loss was $1,641,428 against $1,013,101 a year ago. Non-GAAP operating loss was $604,820 against $636,342 a year ago. Non-GAAP net loss was $616,534 or $0.01 per basic and diluted share against $644,107 or $0.01 per basic and diluted share a year ago.

ChromaDex Signs Material Transfer Agreement with Prominent Australian Research Institute for NIAGEN(TM) Research

ChromaDex Corp. announced that it has entered into a material transfer agreement (MTA) with Murdoch Childrens Research Institute, the preeminent child health research institute in Australia. ChromaDex will provide Murdoch Childrens Research Institute with quantities of its proprietary NIAGEN(TM) nicotinamide riboside (NR) ingredient for research use. ChromaDex's NIAGEN(TM) is the first and only commercially available form of NR, a naturally occurring vitamin B3 derivative found in milk. Published research has shown that NR is perhaps the most effective precursor to boost the co-enzyme NAD+ in the cell. NAD+ is arguably the most important cellular co-factor for improvement of mitochondrial performance and energy. NAD+ is essential in supporting healthy cellular metabolism including the efficient conversation of blood glucose into energy.

ChromaDex Initiates First Human Clinical Study to Confirm ChromaDex's Niagen(TM) Nicotinamide Riboside Will Increase NAD+

ChromaDex Corp. announced the initiation of the first human clinical study for its patented ingredient NIAGEN(TM), the first and only commercially available form of nicotinamide riboside (NR). The study will engage the laboratory of Dr. Charles Brenner, Roy J. Carver Chair of Biochemistry and Professor of Internal Medicine at University of Iowa. Brenner, is credited with discovery of NR as a vitamin in organisms from yeast to people as published in Cell in 2004. The human clinical study is designed to determine the pharmacokinetics (PK) and bioavailability of NIAGEN(TM) as well as provide information about an effective NR dose range in humans. Most importantly, this study aims to confirm earlier animal studies conducted by various universities and research institutes, which showed that oral dosing of the compound results in an increased level of nicotinamide adenine dinucleotide (NAD+) and NAD+ metabolites in the body. As organisms age, NAD+ levels drop, which leads to a decrease in mitochondrial health; this in turn leads to age-related health issues. Low NAD+ levels limit activity of a group of enzymes called sirtuins, which are believed to play a key role in longevity. NAD+ levels can be depleted by lifestyle choices such as overeating and lack of exercise. By boosting NAD+, NR can increase mitochondrial health and induce creation of new mitochondria.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CDXC:US $1.09 USD +0.05

CDXC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Covance Inc $83.66 USD +0.17
Eurofins Scientific SE €218.80 EUR -19.90
Sigma-Aldrich Corp $103.74 USD +0.46
View Industry Companies
 

Industry Analysis

CDXC

Industry Average

Valuation CDXC Industry Range
No financial data is available for CDXC.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHROMADEX CORP, please visit www.chromadex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.